肿瘤标志物联合MRCP对肝外胆道梗阻的临床应用研究  

Clinical Application of Tumor Markers Combined with MRCP in Extrahepatic Biliary Obstruction

作　　者：任曲[1] 杨航燕[1] 宋颖[1] 孙晓丽[1] 

机构地区：[1]北京空军总医院临床检验中心,北京100036

出　　处：《标记免疫分析与临床》2008年第4期201-203,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：评价肿瘤标志物与MRCP联合对肝外胆道梗阻的鉴别诊断价值。采用化学发光免疫分析法测定97例肝外胆道梗阻患者血清CA19-9、CA125及CEA水平,行MRCP显像并进行统计分析。CA19-9在恶性梗阻时的阳性率明显高于CEA和CA125(P<0.01),与MRCP联合检查,诊断准确性可达100%。血清CA19-9检测与MRCP结合鉴别诊断肝外胆道梗阻不仅能提供精确的定位信息,而且可以进行准确的定性判断;CEA和CA125还可以为恶性梗阻的腹腔转移提供可靠信息。To evaluate the value of serum tumor markers combined with MRCP in differentiate diagnosis of extrahepatic biliary obstruction,the serum levels of CA19-9,CA125 and CEA in 97 patients with extrahepatic biliary obstruction were measured by chemiluminescence immunoassay.MRCP were applied at the same time.The results showed that the positive rate of CA19-9 was significantly higher than that of CA125 and CEA in malignant obstructions（P〈0.01）.Combined with MRCP,the accuracy rate of diagnose was significantly high（100%）.The combination detection of CA19-9 and MRCP has important value in the differentiate diagnosis of extrahepatic biliary obstruction to provide excellent accuracy information about the locations of biliary obstructions.The serum levels of CEA and CA125 also provide information of metastasis in malignant obstructions.

关 键 词：CA19-9 CA125 CEA 肝外胆道梗阻 

分 类 号：R446.6[医药卫生—诊断学] R445.2[医药卫生—临床医学]